{"schema_version":"1.0","type":"article","title":"老靶點都很捲，但不是不能賺錢","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.md","lang":"zh-Hant","date":"2026-06-06","publish_at":"2026-06-06T10:30:00+08:00","updated_at":"2026-06-06","category":"商業分析系列","topic":"BD / 授權","tags":["熱門靶點","PD-1","BCMA","CD19","Biotech","BD","差異化"],"summary":"熱門靶點擁擠不代表沒有價值；真正關鍵是公司能否在身位、差異化、適應症切入、技術換代與 BD 對接中找到自己的獲利位置。","key_points":[],"facts":[],"sections":["PD-1、BCMA、CD19 都塞爆了，但不是不能賺錢","01｜靶點到底有多捲？腫瘤是最典型的重災區","02｜Big Pharma 其實比 Biotech 更愛擠熱門靶點","03｜罕見疾病也開始捲：有時候病人真的不夠用了","04｜為什麼大家還是要擠同一棵樹？因為新靶點太難，老靶點比較能去風險","05｜真正的問題不是靶點太老，而是你有沒有差異化","06｜ 靶點很捲，但賺錢機會仍然存在","07｜最反直覺的賺錢方式：果斷停損","08｜🇹🇼 對台灣 biotech 來說，選靶點更要避免「看起來安全，其實最危險」","09｜投資人看靶點，不要只看熱度，要看身位與差異化","結語｜靶點內捲不是問題，沒有策略才是問題"],"references":[],"images":[{"alt":"熱門靶點擁擠不代表沒有價值；真正關鍵是身位、差異化、適應症切入與 BD 對接能力。","url":"https://drugnews.com.tw/assets/articles/old-targets-differentiation-strategy/dcard-01.webp"},{"alt":"在紅海靶點裡，產品能否賺錢取決於是否具備新武器、錯位戰場與清楚的資本配置策略。","url":"https://drugnews.com.tw/assets/articles/old-targets-differentiation-strategy/dcard-02.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/old-targets-differentiation-strategy/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-06）。老靶點都很捲，但不是不能賺錢。https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-06-old-targets-differentiation-strategy-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}